Loading
A phase 2 trial of Tinengotinib, Cadonilimab, Ivonescimab in hepatocellular carcinoma, run by Akeso, now recruiting.
A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC. is a phase 2 interventional study registered as NCT07052253 by Akeso, with 100 participants planned, started 2025-07-18 and due to reach its primary completion in 2027-05-10. Interventions recorded: TT-00420 (tinengotinib), AK104, AK112. Conditions listed: Hepatocellular Carcinoma (HCC). No results are recorded here; the registry entry is the source.
Shares Cadonilimab, Akeso, Advanced hepatocellular carcinoma (BCLC C), Ivonescimab.
Shares Cadonilimab, Akeso, Ivonescimab, Bispecific antibodies.
Shares Cadonilimab, Akeso, Bispecific antibodies, Hepatocellular carcinoma.
Shares Cadonilimab, Akeso, Bispecific antibodies, Hepatocellular carcinoma.
Shares Cadonilimab, Akeso, Ivonescimab, Bispecific antibodies.
Shares Cadonilimab, Akeso, Bispecific antibodies, Immune checkpoint inhibitors.
Shares Cadonilimab, Akeso, Ivonescimab, Bispecific antibodies.
Shares Cadonilimab, Akeso, Ivonescimab, Bispecific antibodies.